E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Obsessive-compulsive disorder
|
|
E.1.1.1 | Medical condition in easily understood language |
Obsessive-compulsive disorder
|
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the prolonged efficacy of ketamine in alleviating symptoms of patients with OCD (7 days) |
|
E.2.2 | Secondary objectives of the trial |
To investigate the prolonged efficacy of ketamine in alleviating symptoms of patients with OCD (24 hours) To investigate the prolonged efficacy of ketamine in alleviating symptoms of patients over the course of 7 days. (VAS) To investigate the effects of ketamine on neuropsychological function under stress in patients with OCD. To investigate the effects of ketamine on hormonal stress response measured by salivary cortisol levels in patients with OCD. To investigate the effects of ketamine on vegetative stress response measured by blood pressure and heart rate in patients with OCD. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Primary diagnosis of obsessive-compulsive disorder
A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale
Age of at least 18 years and ability to provide written informed consent
One previous treatment for OCD
|
|
E.4 | Principal exclusion criteria |
Any history of current or past psychotic disorder
A manic episode within the preceding three years
Current or unstable remitted substance abuse or dependence except nicotine
Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception
Any current severe personality disorder except comorbid anankastic personality disorder
Current unstable suicidality
Morbus Raynaud
Unstable hypertension
Any other severe and unstable cardiovascular disease
Untreated hyperthyroidism
Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing)
Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH
Inability to follow the study protocol or adhere to operational requirements
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Significant reduction of symptoms measured by Yale-Brown Obsessive-Compulsive Scale after application of intravenous ketamine
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 and 7 days after each infusion |
|
E.5.2 | Secondary end point(s) |
Treatment success for the individual patient, defined as 35% reduction in Y-BOCS scores from baseline. Symptom alleviation measured by YBOCS and OCD visual analogue scale score will persist for up to seven days Significant reduction of obsessive thoughts after ketamine infusion, measured by OCD visual analogue scale in comparison to placebo Effects of ketamine infusion on neuropsychological functions under stress measured by WCST, SSRT, N-back and ToH Effects of ketamine infusion on hormonal stress response measured by salivary cortisol levels Effects of ketamine infusion on vegetative stress response measured by blood pressure and heart rate Effects of ketamine infusion on subjective stress levels after acute stress induction measured by a visual analogue scale. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-YBOCS Score: baseline, one and seven days after each infusion
-subjective obsessions: before, during, immediately after infusion and once every day post infusion for seven days
-neurocognitive tests, subjective stress, hormonal and vegetative stress response: 3 time points, 1 baseline, 1 after each infusion |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is defined as timepoint when the last participant underwent all infusion procedures and completed all symptom assessments including an end of study examination
Trial will end earlier if patients safety is at risk |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |